BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive

eliquis
Eliquis grew 40% year over year in the second quarter. (Bristol-Myers Squibb)

Last year, Pfizer and Bristol-Myers Squibb’s Eliquis replaced Johnson & Johnson’s Xarelto as the leader of the novel oral anticoagulant class. And now it’s about to unseat an even bigger foe: warfarin.

The blockbuster is poised to overtake the old-guard clot-fighter, Bristol CEO Giovanni Caforio told analysts on last week’s second-quarter earnings call, and when it does, it’ll lead all oral anticoagulants.

The partners are “now closing the gap” between Eliquis and warfarin, and the lead should change hands “within the coming weeks,” Johanna Mercier, head of U.S. commercial for the New Jersey drugmaker, said on the call.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: Bristol-Myers surprise: Threatened I-O drug Opdivo stands its ground in lung cancer

BMS and Pfizer have a big second-quarter performance from Eliquis to thank for putting the next-gen blood thinner within striking distance. Nearly six years after launching, the product posted 40% growth for the quarter, lifting sales to $1.65 billion. It’s “just an incredible growth story,” Mercier said.

And it’s not over, executives stressed. “We … continue to see prescription trends that signify further expansion of the NOAC class,” CFO Charlie Bancroft said, predicting a “significant further decline in warfarin usage.” Right now, warfarin boasts nearly 40% share of all prescriptions for oral anticoagulants, but it can claim only about half of that share of new prescriptions.

RELATED: Pfizer, BMS' Eliquis takes J&J's next-gen anticoagulant market-share crown

Of course, Eliquis’ leading rivals—Xarelto and Boehringer Ingelheim’s Pradaxa, which for years looked down on Eliquis as an underperforming, third-to-market drug—are eager to snap up share from warfarin, too. But “as NOAC usage expands, we expect Eliquis to maintain its leading position in the class with substantial growth momentum going forward,” Bancroft said.

That’s not to say market expansion opportunities that could benefit all three NOAC contenders aren’t still out there. In addition to the “30% of those TRx patients on warfarin that are actually uncontrolled,” there are roughly 1 million patients who are diagnosed and not treated, plus another 1 million that are undiagnosed, Mercier added.

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.